Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3206189rdf:typepubmed:Citationlld:pubmed
pubmed-article:3206189lifeskim:mentionsumls-concept:C0019425lld:lifeskim
pubmed-article:3206189lifeskim:mentionsumls-concept:C0055530lld:lifeskim
pubmed-article:3206189lifeskim:mentionsumls-concept:C0238052lld:lifeskim
pubmed-article:3206189lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:3206189lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:3206189pubmed:issue5lld:pubmed
pubmed-article:3206189pubmed:dateCreated1989-1-27lld:pubmed
pubmed-article:3206189pubmed:abstractTextC27-steroid 26-hydroxylase activity in fibroblasts from two heterozygotes for CTX was determined, using an optimized enzyme assay. With 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol, 5 beta-cholestane-3 alpha,7 alpha-diol, 7 alpha-hydroxy-4-cholestane-3-one or 7 alpha-hydroxycholesterol as substrates, the activities were about 50% of those of control cells. The Km for the substrates was not increased in the CTX heterozygotes. These findings support that deficiency of the C27-steroid 26-hydroxylase is the primary enzymatic defect in CTX.lld:pubmed
pubmed-article:3206189pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3206189pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3206189pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3206189pubmed:languageenglld:pubmed
pubmed-article:3206189pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3206189pubmed:citationSubsetIMlld:pubmed
pubmed-article:3206189pubmed:statusMEDLINElld:pubmed
pubmed-article:3206189pubmed:monthSeplld:pubmed
pubmed-article:3206189pubmed:issn0036-5513lld:pubmed
pubmed-article:3206189pubmed:authorpubmed-author:SkredeSSlld:pubmed
pubmed-article:3206189pubmed:authorpubmed-author:BjörkhemIIlld:pubmed
pubmed-article:3206189pubmed:authorpubmed-author:GrundySSlld:pubmed
pubmed-article:3206189pubmed:authorpubmed-author:EastCClld:pubmed
pubmed-article:3206189pubmed:authorpubmed-author:KvittingenE...lld:pubmed
pubmed-article:3206189pubmed:issnTypePrintlld:pubmed
pubmed-article:3206189pubmed:volume48lld:pubmed
pubmed-article:3206189pubmed:ownerNLMlld:pubmed
pubmed-article:3206189pubmed:authorsCompleteYlld:pubmed
pubmed-article:3206189pubmed:pagination425-9lld:pubmed
pubmed-article:3206189pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:meshHeadingpubmed-meshheading:3206189-...lld:pubmed
pubmed-article:3206189pubmed:year1988lld:pubmed
pubmed-article:3206189pubmed:articleTitleReduced C27-steroid 26-hydroxylase activity in heterozygotes for cerebrotendinous xanthomatosis.lld:pubmed
pubmed-article:3206189pubmed:affiliationInstitute of Clinical Biochemistry, University of Oslo, Rikshospitalet, Norway.lld:pubmed
pubmed-article:3206189pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3206189pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3206189pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:3206189pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed